Pulmonary Arterial Hypertension

News Pulmonary Arterial Hypertension

• Bayer’s Riociguat submitted for regulatory approval in the U.S. and EU

  Bayer HealthCare has submitted the oral investigational drug Riociguat to treat patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) for regulatory approval in the United States and in the European Union. “These regulatory submissio more

• Actelion submits the registration dossier for macitentan to EMA

  Actelion announced that the submission of the Marketing Authorisation Application (MAA) for macitentan (Opsumit®) for the treatment of patients with pulmonary arterial hypertension to the EMA has been accepted. The EMA will now start the formal review process.The United States Food and Drug Administ more

• Actelion submits a NDA for macitentan for the treatment of patients with pulmonary arterial hypertension

  Actelion announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for macitentan (Opsumit®) for the treatment of patients with pulmonary arterial hypertension.Macitentan, a novel oral dual endothelin receptor antagonist, was studied i more

Publications Pulmonary Arterial Hypertension

• The TGFbeta‐BMP Signalling Pathway in pulmonary vascular homeostasis and disease

  Abstract  Germ‐line mutations in the Bone Morphogenetic Protein type II receptor (BMPR2; BMPR‐II) gene, a Transforming Growth Factor beta (TGFβ) receptor superfamily member, cause the majority of heritable pulmonary arterial hypertension (PAH) cases. PAH is a subset of pulmonary hypertension (PH) more

• The influence of gender on the development of pulmonary arterial hypertension

  Abstract  Pulmonary arterial hypertension (PAH) is a progressive disease in which increased pulmonary arterial pressure and remodelling eventually lead to right heart failure and death. Idiopathic and familial PAH occur far more frequently in women than in men. Historically, investigations into th more

• Treprostinil for the treatment of pulmonary arterial hypertension

  Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by increasing pulmonary vascular resistance leading to right ventricular failure and death. Treprostinil is a stable prostacyclin analog approved for the treatment of PAH to improve exercise capacity. In the setti more

Market studies Pulmonary Arterial Hypertension

• Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

  GBI Research in its report “Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles” presents the use of endpoints or outcomes measures in respiratory disease’s clinical trials. In this report, endpoint us more

• Pulmonary Arterial Hypertension – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2012', provides an overview of the Pulmonary Arterial Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Arterial Hypertension, complete with l more

• Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

  GBI Research, the leading business intelligence provider, has released its latest research “Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion”, which provides insights into the anti-hypertensives therapeutics market more

Websites Pulmonary Arterial Hypertension